Inventiva raises €48m in Euronext IPO
Raising €48m by the sale of 5.7 million shares at €8.50, French Inventiva S.A. is set to secure capital to further its late-stage products until H1/2019.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2213 entries already.
Entries by Thomas Gabrielczyk
Vifor Pharma expands ChemoCentryx partnership
Swiss Galenica subsidiary Vifor Pharma has licensed commercialisation rights for ChemoCentryx Inc’s complement C5a receptor (C5aR ) blocker Avacopan (CCX168) in Asia and the Middle East. The drug is currently undergoing Phase III testing in patients with rare renal diseases.
Novimmune partners with LegoChem Biosciences
Swiss antibody specialist Novimmune has entered a R&D collaboration on antibody drug conjugates (ADC) with the South Korean conjugation chemistry expert LegoChem Biosciences.
Oncoinvent closes US$25m private placement
After having issued a patent on its lead cancer treatment Radspherin, Oslo-based Oncoinvent A/S has bagged the funding needed to go ahead to proof-of-concept.
AMR: EU Commission awards €45,000
Vytenis Andriukaitis, Commissioner for Health and Food Safety, has awarded the EU Health Award for NGOs fighting Antimicrobial Resistance to BEUC for lobbying to reduce the threat of antimicrobial resistance (AMR).
Prexton Therapeutics gets €29m cash injection
Merck Serono spin-out Prexton Therapeutics has closed a Series B financing round cashing in US$31m for pushing Phase II testing of its Parkinson’s compound PXT002331.
Biotechs concerned over EPO rules
Life Sciences stakeholders in Europe and abroad are voicing their concerns about the European Patent Offices’ initiative to shorten the time for the examination of patents from up to 56 months to 12 months.
Molecule prevents oedema
French researchers have identified a regulator which controls blood vessel permeability. Their findings open up the possibility to develop drugs preventing oedema that occur in large indications such as stroke or congestive heart failure.
Fighting AMR efficiently
Major European stakeholders have released statements on how to fight antimicrobial resistance more effectively. Regulatory agencies such as EFSA and EMA call for locally adapted combination strategies while biotech companies advocate for more support in antibiotics R&D.
uniQure gets FDA breakthrough status for AMT-060
Dutch gene therapy specialist uniQure Biopharma BV will be able to rapidly develop its haemophilia B gene therapy AMT-060. Based on data of a Phase I/II safety study, the FDA granted breakthrough therapy designation for the new way to substitute the heritable lack of blood clotting factor IX.